Cunningham Ann Michelle

Director at ALTERITY THERAPEUTICS LTD · on record since Apr 29, 2026
CHIEF COMMERCIAL OFFICER at Vistagen Therapeutics, Inc. · on record since May 4, 2021
Director at Vistagen Therapeutics, Inc. · on record since Jan 14, 2019

Insider trading activity of Cunningham Ann Michelle

Transactions on record: 10; since Jan 14, 2019

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Sep 11, 2025

Figures computed from official regulatory filings — .

Companies where Cunningham Ann Michelle has traded

Vistagen Therapeutics, Inc.10 tx · Sep 11, 2025

Track record of Cunningham Ann Michelle

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Cunningham Ann Michelle

Co-insiders of Cunningham Ann Michelle

Adler Reid G.Vistagen Therapeutics, Inc.
Anderson Cynthia LynnVistagen Therapeutics, Inc.
Angelov Angel SVistagen Therapeutics, Inc.
Babarczy Julian MichaelALTERITY THERAPEUTICS LTD
Cato Allen EasleyVistagen Therapeutics, Inc.
CATO HOLDING COVistagen Therapeutics, Inc.
COMMODORE CAPITAL LPVistagen Therapeutics, Inc.
Cote Elissa S.Vistagen Therapeutics, Inc.
Curley JoanneVistagen Therapeutics, Inc.
DOTSON JERROLD DUANEVistagen Therapeutics, Inc.
Edick Paul RVistagen Therapeutics, Inc.
FitzPatrick Margaret MVistagen Therapeutics, Inc.
GIN JERRY BVistagen Therapeutics, Inc.
Ginski Mark JVistagen Therapeutics, Inc.
Gozlan Lawrence BernardALTERITY THERAPEUTICS LTD
JONES STEPHANIEVistagen Therapeutics, Inc.
Koh Bong YVistagen Therapeutics, Inc.
Macnish Niven Abby SarahALTERITY THERAPEUTICS LTD
Marks Peter AshleyALTERITY THERAPEUTICS LTD
MCPARTLAND MARK A.Vistagen Therapeutics, Inc.
Platinum Long Term Growth VII, LLCVistagen Therapeutics, Inc.
Prince Joshua S.Vistagen Therapeutics, Inc.
RICE A. FRANKLINVistagen Therapeutics, Inc.
Rotunno Mary L.Vistagen Therapeutics, Inc.
SAXE JON SVistagen Therapeutics, Inc.

This page republishes public regulatory disclosures.

Company	Filed	Type	Qty	Value · USD	Src
Vistagen Therapeutics, Inc.Listing on record	Sep 11, 2025	AwardD (derivative)	17,600	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Sep 10, 2024	AwardD (derivative)	14,100	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Mar 6, 2024	AwardD (derivative)	12,500	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Mar 3, 2022	AwardD (derivative)	150,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	May 4, 2021	AwardD (derivative)	300,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Jan 4, 2021	AwardD (derivative)	75,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Apr 27, 2020	AwardD (derivative)	75,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Oct 22, 2019	AwardD (derivative)	75,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	May 28, 2019	AwardD (derivative)	50,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Jan 14, 2019	AwardD (derivative)	25,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC

Company	Filed	Type	Qty	Value · USD	Src
Vistagen Therapeutics, Inc.Listing on record	Sep 11, 2025	AwardD (derivative)	17,600	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Sep 10, 2024	AwardD (derivative)	14,100	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Mar 6, 2024	AwardD (derivative)	12,500	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Mar 3, 2022	AwardD (derivative)	150,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	May 4, 2021	AwardD (derivative)	300,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Jan 4, 2021	AwardD (derivative)	75,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Apr 27, 2020	AwardD (derivative)	75,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Oct 22, 2019	AwardD (derivative)	75,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	May 28, 2019	AwardD (derivative)	50,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
Vistagen Therapeutics, Inc.Listing on record	Jan 14, 2019	AwardD (derivative)	25,000	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC